Citius Oncology Other Current Assets 2022-2025 | CTOR

Citius Oncology other current assets from 2022 to 2025. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.

Citius Oncology Other Current Assets 2022-2025 | CTOR

Citius Oncology other current assets from 2022 to 2025. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
CSL (CSLLY)$78.5B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Moderna (MRNA)$12.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B